Sheryl Stevenson

Sunir J. Garg, MD, explores the nuances of endophthalmitis, distinguishing between infectious and non-infectious responses for effective patient management.

Research reveals significant vision improvements and extended treatment intervals with aflibercept 8 mg for age-related macular degeneration and diabetic edema patients.

Phase 2 STARLIGHT study participants, particularly those with the macular phenotype, experienced meaningful gains in visual acuity at 48 weeks.

The incision-free therapeutic for keratoconus is expected to be commercially available in early 2026, according to the company.

Bedrood describes improved visualization of the ciliary body, efficient setup, and favorable postoperative outcomes.

Innovations in selective laser trabeculoplasty and laser cyclophotocoagulation focus on procedural efficiency, patient comfort, and evolving first-line treatment strategies.

John P. Berdahl, MD, discusses advanced lens options for patients with pseudoexfoliation, highlighting considerations for successful longterm outcomes.

In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.

A new study reveals enhanced safety and efficacy in epi-on cross-linking for keratoconus, utilizing oxygen-rich boost goggles during treatment.

The 18-month extension of the GATHER2 trial indicated continued benefit for patients receiving avacincaptad pegol, with efficacy gains increasing over time.

Attendees of the AAO 2025 annual meeting will have a chance to preview the virtual technician training platform on October 19, at 10:30 am in the Academy Theater, Hall WB1, Booth 2761.

The approval of the third-generation trifocal intraocular lens broadens the range of advanced lens options available for patients in the US.

Singh highlights how understanding the “why” behind diagnostics and procedures boosts technician confidence, fosters pride, and strengthens their role in patient care.

The video-driven platform equips ophthalmic practices with tools to standardize education, improve workflow, and foster technician engagement.

Subramanian discusses how subtle retinal and optic nerve findings can point to underlying neurologic disease.

Smith highlights advances in interventional glaucoma, including first-line SLT, emerging surgical options, and co-management strategies, during the Ophthalmology Times and Optometry Times EyeCon 2025 conference.

Residents across ophthalmology, optometry, and retina care were recognized for leadership, research, and dedication to advancing patient care.

By combining anatomical fidelity with reproducibility, NRSS offers a novel way to train surgeons, validate clinical trials, and expand access to advanced techniques worldwide.

Dr. Tanna will kick off the new monthly subspecialty education series with a virtual session on September 9, 2025, focused on using OCT imaging and perimetry to track glaucoma progression.

Course director Robert S. Feder, MD, shares how the monthly Zoom sessions aim to deliver clinical pearls and foster cross-subspecialty learning.

As myopia becomes a worldwide epidemic, the upcoming Paris workshop on September 8, 2025, will convene global leaders to discuss strategies, research priorities, and new treatment pathways.

Ahead of the September 8 meeting in Paris, the program co-chair of the event and current president of the American Academy of Ophthalmology discusses how the workshop aims to shape consensus on guidelines, research priorities, and emerging therapies in myopia control.

In episode 1, Bill Trattler, MD, shares practical advice on documentation, patient communication, keratoconus management, and advanced lens technology.

Dan Ignaszewski explains how the national advocacy campaign aims to unite patients, researchers, and clinicians to protect NEI’s independence and ensure vision research funding.

Extend the summer at EyeCon 2025—where clinical insight meets coastal vibes—September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida.

Marguerite B. McDonald, MD, FACS, shares a front-row view of ophthalmology’s “revolution with a capital R."

The ADAPT study will evaluate the safety and effectiveness of the Calibreye surgical system in up to 70 patients with refractory glaucoma.

The Eye Care Network connected with Haller to hear her vision for Wills Eye Hospital, her priorities as CEO, and what lies ahead for the field of ophthalmology.

The DRD Cure Accelerator, highlighted at the CCOI-Stanford Summit, is a global initiative advancing clinical research and collaborations to eliminate vision loss from diabetic retinal disease.